Financials
Financial year 2025
CLINIMETRICS from Ukkel, company number BE0426756052, closed financial year 2025 with a result of € 24.4 million after tax. For that financial year CLINIMETRICS recorded revenue of € 308,168 and equity of € 192.5 million. Compared with financial year 2024, the result moved from € 165.3 million to € 24.4 million. The company is profitable. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.
€ 192.5 million
▲ 15% vs 2024
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ 24.4 million
▼ 85% vs 2024
Profit after tax over the fiscal year.
€ 796,039
▼ 93% vs 2024
Cash and bank balances on the last day of the fiscal year.
Stays in the company
No dividend for 2025. Retained profit grew to € 192.4 million.
People and assets in 2025
€ 16,022
▼ 50% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 4 million
▲ 287% vs 2024
€ 665,395 is repaid this year. At this pace the long-term loan is gone in ≈ 6 years.
€ 83,361
▲ 126% vs 2024
Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 71 days on average.
Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Revenue | - | - | € 298,744 | € 308,168 | ▲ 3% |
| Gross margin | € 299,296 | € 331,097 | - | - | |
| Profit after taxes | € 161,437 | € 1,137,204 | € 165,306,292 | € 24,394,578 | ▼ 85% |
| Equity | € 12,054,869 | € 13,192,072 | € 168,112,001 | € 192,506,579 | ▲ 15% |
| Total debts | € 2,869,069 | € 2,364,184 | € 7,181,664 | € 5,189,817 | ▼ 28% |
| Cash | € 2,812,520 | € 2,663,994 | € 11,292,419 | € 796,039 | ▼ 93% |
| Land & buildings | € 3,007,781 | € 2,941,019 | € 2,874,257 | € 5,102,835 | ▲ 78% |
| Retained profit | € 11,992,869 | € 13,130,072 | € 168,050,001 | € 192,444,579 | ▲ 15% |
| Dividend | € 0 | € 0 | € 10,386,364 | € 0 | ▼ 100% |
| Bank debt | € 1,049,408 | € 1,045,699 | € 1,045,842 | € 4,045,833 | ▲ 287% |
| Balance sheet total | € 14,923,938 | € 15,556,256 | € 175,293,665 | € 197,696,396 | ▲ 13% |
Key figures of CLINIMETRICS, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to CLINIMETRICS?
What happened at CLINIMETRICS in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- Marc BUYSE stepped down as director. NBB
- Nitya SRL stepped down as director. NBB
- Hetafin SRL stepped down as director. NBB
- Cyco Invest SRL stepped down as director. NBB
- New annual accounts for financial year 2025: profit of € 24.4 million (▼ 85% vs 2024). filed late Source: NBB ↗
- Nitya SRL became a director. NBB
- Hetafin SRL became a director. NBB
- Cyco Invest SRL became a director. NBB
In short
From € 161,437 profit in 2022 to € 24.4 million profit in 2025.
Paid € 1.1 million in corporate taxes since 2022.
Best year ever: 2024, with € 165.3 million profit.
Paid out € 10.4 million in dividends to the owners in total.
A new publication or filing at CLINIMETRICS? We notify you, reason included.
Follow CLINIMETRICSDatabakkes Pro
Know what changes at your customers, suppliers and competitors. Without reading an annual account.
- Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
- We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
- In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.
Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.
De Lijn 8 June 2026 New annual account 2025
filed on 8 June 2026
What was left
€ 20 k ▼ 91%
Money in the bank
€ 178 k ▼ 98%
Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit
Management
It owns 50.7% of IDDI GROUP, 27.4% of ONE2TREAT, 25% of NITYA and IDDI itself.
Directors
According to the 2025 annual accounts
Marc BUYSE
Director
since 2024 · until 2029
since 2025 · until 2029
Director · represented by Mathieu Buyse
since 2025 · until 2029
Establishments
Establishment units
Physical locations of this company
de Perckestraat 76
1180 Ukkel
Waterloosesteenweg 1377
1180 Ukkel
Active since 1 January 1985
Who else lives here?
A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.
All companies at this address →What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Details
- Company number
- 0426.756.052
- VAT number
- BE 0426.756.052
- Registered office
- de Perckestraat 76, 1180 Ukkel
- Names & denominations
- CLINIMETRICS
- Enterprise type
- Rechtspersoon
- Legal form
- Public limited company
- Legal situation
- Normale toestand
- Start date
- 10 January 1985
- Peppol
- Active · Active since 1 Apr 2026
- Activities · NACE
Marktonderzoekbureaus
Markt- en opinieonderzoekbureaus